Y-mAbs Therapeutics, Inc. Shares Sold by Point72 Asset Management L.P. - MarketBeat
YMAB Stock | USD 9.40 0.37 3.79% |
About 67% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.
YMAB |
Y-mAbs Therapeutics, Inc. Shares Sold by Point72 Asset Management L.P. MarketBeat
Read at news.google.com
Y MAbs Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Y MAbs Fundamental Analysis
We analyze Y MAbs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y MAbs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Y MAbs is currently under evaluation in target price category among its peers.
Y mAbs Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
Peers
Y MAbs Related Equities
BLUE | Bluebird Bio | 1,589 | ||||
ARQT | Arcutis Biotherapeutics | 5.88 | ||||
MRUS | Merus BV | 2.39 | ||||
PASG | Passage Bio | 0.38 | ||||
MIRM | Mirum Pharmaceuticals | 0.14 | ||||
LRMR | Larimar Therapeutics | 0.33 | ||||
RVMD | Revolution Medicines | 0.36 | ||||
EWTX | Edgewise Therapeutics | 0.43 | ||||
ZNTL | Zentalis Pharmaceuticals | 0.96 | ||||
SNDX | Syndax Pharmaceuticals | 1.11 | ||||
BDTX | Black Diamond | 1.20 | ||||
ERAS | Erasca | 1.52 | ||||
KRON | Kronos Bio | 2.00 | ||||
TVTX | Travere Therapeutics | 2.29 | ||||
CCCC | C4 Therapeutics | 2.78 | ||||
DAWN | Day One | 2.89 | ||||
STRO | Sutro Biopharma | 3.18 | ||||
PCVX | Vaxcyte | 3.99 | ||||
GBIO | Generation Bio | 4.20 | ||||
MRSN | Mersana Therapeutics | 7.39 |
Complementary Tools for YMAB Stock analysis
When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
CEOs Directory Screen CEOs from public companies around the world | |
Transaction History View history of all your transactions and understand their impact on performance | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |